Top Buy Stocks
Sign In
Invest in GALT
$2.51
+0.0600 (+2.45%)
At Close: Jul 11, 2025
NORCROSS, Ga., May 12, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypert
Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update
08:00am, Monday, 31'st Mar 2025
NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and
Galectin Therapeutics to Present at the 2025 MASH-TAG Conference
08:00am, Friday, 10'th Jan 2025
NORCROSS, Ga., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the top-line resu
Why Is Small Cap Galectin Therapeutics Stock Trading Lower On Friday?
10:29am, Friday, 20'th Dec 2024
On Friday, Galectin Therapeutics, Inc. GALT released results from its global Phase2/3 NAVIGATE trial evaluating belapectin in patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) cir
NORCROSS, Ga., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced results from its globa
Here's Why Galectin Therapeutics (GALT) is Poised for a Turnaround After Losing -31.83% in 4 Weeks
10:35am, Monday, 09'th Dec 2024
The heavy selling pressure might have exhausted for Galectin Therapeutics (GALT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Stre
NORCROSS, Ga., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the presentation of th
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update
08:00am, Thursday, 14'th Nov 2024
NORCROSS, Ga., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and p
NORCROSS, Ga., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that three abstracts f
Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
08:30am, Tuesday, 03'rd Sep 2024
NORCROSS, Ga., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that Joel Lewis, Chie
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update
08:00am, Tuesday, 13'th Aug 2024
NORCROSS, Ga., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and p
Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer
08:00am, Thursday, 01'st Aug 2024
NORCROSS, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khu
Meet the 10 biggest megadonors in the 2024 election cycle so far
01:47pm, Tuesday, 18'th Jun 2024
Following record-breaking fundraising by candidates in the 2022 midterms, this year's election cycle is shaping up to be another big one for megadonors.
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress
08:00am, Tuesday, 04'th Jun 2024
NORCROSS, Ga., June 04, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced that it will attend the EASL
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update
08:00am, Wednesday, 15'th May 2024
NORCROSS, Ga., May 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and pr
